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Abstract: Nutritional immunity is a form of innate immunity widespread in both vertebrates and
invertebrates. The term refers to a rich repertoire of mechanisms set up by the host to inhibit
bacterial proliferation by sequestering trace minerals (mainly iron, but also zinc and manganese). This
strategy, selected by evolution, represents an effective front-line defense against pathogens and has
thus inspired the exploitation of iron restriction in the development of innovative antimicrobials or
enhancers of antimicrobial therapy. This review focuses on the mechanisms of nutritional immunity,
the strategies adopted by opportunistic human pathogen Staphylococcus aureus to circumvent it,
and the impact of deletion mutants on the fitness, infectivity, and persistence inside the host. This
information finally converges in an overview of the current development of inhibitors targeting
the different stages of iron uptake, an as-yet unexploited target in the field of antistaphylococcal
drug discovery.
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1. Iron and Nutritional Immunity
1.1. Iron: A Double-Edged Sword
Iron is very abundant in the biosphere, being the fourth most abundant element in the earth’s
crust and the most abundant transition metal in the human body [1]. All living organisms, except for
Borrelia burgdorferi [2] and some Lactobacilli [3], need iron to fulfill a plethora of biological functions.
During evolution, iron has acquired a pivotal role in metabolism due to its favorable chemical
properties that allow the formation of coordination bonds with electronegative atoms and the transition
between the ferrous (Fe(II)) and ferric (Fe(III)) oxidation states. Indeed, iron can adopt different
coordination states with different ligands containing oxygen, nitrogen, and sulfur. In hemoglobin
(Hb) and myoglobin (Mb), for instance, iron is coordinated by the four porphyrin nitrogen atoms
of protoporphyrin IX and a histidine residue known as proximal histidine [4]. Coordination can be
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incomplete, thus mediating a ligand transport function, as in the case of Hb, or a ligand-activation
function, as in the case of oxygenases. In other cases, coordination can be complete, as in cytochromes,
where iron shuttles between the two Fe(II) and Fe(III) redox states without changing its coordination
environment [5]. The protein microenvironment also finely modulates the Fe(II)/Fe(III) redox potential
that in most cases in living organisms is well below the standard value of +0.7 V [5,6]. In Hb, the heme
iron is stabilized in the Fe(II) form within the hydrophobic heme pocket.
In aqueous solutions and in the presence of oxygen, iron is in the ferric oxidation state, which
is poorly soluble [7,8], and needs to bind to proteins or hydrophilic chelators to be biologically
available. Free iron is a double-edged sword, being essential for life but also extremely dangerous
because of its chemical reactivity. Indeed, ferric iron participates in Fenton-type redox chemistry
that generates reactive hydroxyl radicals, noxious for most macromolecules including proteins and
DNA [9]. The search for a compromise between the versatility of iron as a protein cofactor and its
potential adverse effects has shaped the evolution of systems, identified in plants, vertebrates, and
invertebrates, that allow eukaryotes to store large amounts of this metal in a form unavailable to
the bacterial invaders. Sequestration of iron within proteins has, thus, the double beneficial effect
of limiting and modulating its reactivity and inhibiting bacterial proliferation. The concentration
of free iron in human fluids was estimated to be around 10−18 M [10], several orders of magnitude
lower than the concentration needed to sustain bacterial replication (low micromolar range, [11]).
Iron withdrawal to limit nutrients available to bacteria and thus inhibiting their proliferation in the
human host has been named “nutritional immunity” in the 1970s by Weinberg [12]. Nutritional
immunity has a constitutive character, with basal expression of iron-binding proteins and the control
on iron absorption to limit the concentration of free iron in the body. Moreover, this first-line defense
is stimulated under infection/inflammation conditions and leads to the so-called hypoferremia of
infection [13,14] (vide infra).
1.2. The Mechanisms of Nutritional Immunity
Nutritional immunity is a well-established first-line defense against pathogens and represents
a very effective form of innate immunity that, indeed, allows invertebrates, like cockroaches [15],
to survive in environments where bacteria proliferate [6]. The activation of innate immunity needs
recognition by the human host of a specific pathogen-associated molecular patterns (PAMPs) by pattern
recognition receptors (PRRs) [16,17]. An example of this mechanism of recognition of molecular
determinants shared by multiple pathogens is mannose receptors, expressed on the surface of
mammalian macrophages. Stimulation of PRRs leads to cytokine production and the induction of
cytokines-dependent genes [17,18].
Iron absorption in the intestine is controlled by the expression of divalent metal transporter 1
(DMT1) on the luminal side of enterocytes [19,20] and, on the basal side, by ferroportin, that transports
iron into the bloodstream. DMT1 actively transports iron into enterocytes and is also expressed on
macrophages [18] and in endosomes during the transferrin cycle ([11] and references within). Transferrin
cycle is a form of receptor-mediated endocytosis of iron-bound transferrin. The transferrin-receptor
complex undergoes a pH-mediated conformational change in the endosomes with the release of free
iron that is finally transported into the cytoplasm by DMT1. This proton co-transporter transfers only
ferrous iron, thus Fe(III) must be reduced to Fe(II) by a specific reductase in the membrane before
active transport takes place [11]. Iron is stored inside enterocytes and other cells like erythroblasts,
hepatocytes, and macrophages in complex with ferritin (Figure 1). Ferritin is a ubiquitous protein
playing a key role in iron detoxification and storage in a bioavailable form [21]. This heteropolymeric
complex is formed by 24 subunits (L- and H-ferritin) and is able to bind up to 4500 iron ions behaving
as a nanocage for this metal [22]. Ferrous iron is oxidized to ferric by the ferroxidase activity of the
H-subunits and is stored inside the cage as crystallite with phosphate and hydroxide ions (ferrihydrite).
Iron is transported throughout the body by serum transferrin (Figure 1), a protein of the transferrin
superfamily that comprises serum transferrin itself, ovotransferrin and lactoferrin [23]. Ferroportin
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is the specific iron export protein that mediates iron efflux out of the cell in the ferrous form. This
export protein allows iron absorption by enterocytes and iron efflux from macrophages [11]. Iron is
immediately oxidized by a specific membrane ferroxidase and loaded as ferric iron onto transferrin
for tissue distribution. Serum transferrin is the main iron transport protein in serum and has a
typical bilobate shape, with a mixed α/β structure. The two lobes are connected by an unstructured
linker region and undergo a large open-to-close transition upon iron binding [24,25]. Each transferrin
molecule can bind two ferric iron ions, one in each lobe. The fraction of transferrin saturated by iron is
about 30% in the healthy adult [10], which accounts for a free iron concentration of about 10−18 M.
This saturation increases to 70% in the infant, due to a combination of moderate hyperferremia and a
sub-optimal expression of transferrin. Under infection conditions, the concentration of free iron in
body fluids is so low that transferrin saturation drops to 5%. Since transferrin is an acute-phase protein,
the observed drop in transferrin saturation during infection results from a combination of increased
plasma concentration of the protein and decreased iron absorption [6]. Iron bound to transferrin
accounts for only 1% of total body content, whereas more than 80% of iron is sequestered inside
heme-binding proteins, including Hb (60%), Mb (5%), cytochromes and iron-dependent enzymes.
Lactoferrin (Figure 1) is secreted by exocrine glands and expressed and stored also in specific granules
of neutrophils, from which it is released upon induction [26]. It was identified at concentrations as high
as 8 mg/mL in many body fluids like colostrum, tears, sweat and seminal fluid [26]. Lactoferrin has a KD
for Fe(III) of 10−20 M [14,27], much lower than that of transferrin [8], supporting sequestration, rather
than the transport function for the former protein [28]. Indeed, lactoferrin is able to uptake iron from
transferrin and direct it to the liver. Transferrin receptors are expressed on macrophages, erythrocytes,
hepatocytes, and virtually all cell types with few exceptions. Besides iron withdrawal, mammals
have developed a series of mechanisms devoted to preventing iron overload upon degradation of
heme-containing proteins. Since Hb binds the larger fraction of total body iron, most of the strategies
for free-iron limitations concentrate on Hb/heme removal from circulation upon erythrocytes lysis.
Haptoglobin (Hp) and hemopexin (Figure 1) have evolved to bind Hb and heme, respectively. Hp
binds Hb with high affinity, with a KD for dimeric Hb in the order of 10−12 M [14]. The circulating Hp
reaches saturation at about 1.5 g/L free Hb [29] and is thus able to face efficiently moderate hemolysis.
The Hp/Hb complex is specifically recognized by receptors on macrophages and hepatocytes [14,29]
and readily degraded. Two polymorphic variants of Hp have been identified, Hp-1 and Hp-2, giving
three different phenotypes: Hp1-1, Hp1-2, and Hp2-2, that differ in the quaternary structure and Hb
binding capacity [30]. Hp2-2 is the phenotype with the lowest Hb binding capacity and is associated
with a worse outcome of infections, higher cardiovascular risk and increased diet requirement of
vitamin C due to the oxidative stress induced by free circulating heme [29,31]. Hemopexin is also an
acute-phase protein expressed by hepatocytes that binds free heme with a KD lower than 10−12 M and
is recycled within hepatocytes once the complex is recognized by CD91 receptors [14]. Saturation of
Hp and hemopexin by Hb and heme, respectively, has been reported to be more dangerous for the
development of infections than transferrin saturation [10].
1.3. Nutritional Immunity under Infection Conditions
Under infection conditions, the basal nutritional immunity is reinforced, and additional
mechanisms are activated to starve microbes of iron. The master regulator of iron uptake and
distribution under infection conditions is the peptide hormone hepcidin. This 25- amino acid peptide
is produced by the liver under physiological conditions and its expression is mainly regulated at
the transcriptional level. The expression of the protein is positively regulated by hypoxia and active
erythropoiesis and negatively regulated by a decrease in plasma iron concentration [32,33]. Under
infection and inflammation conditions, interleukin-6 activates the expression of hepcidin through the
Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathway [8,33]. Stimulation
of hepcidin expression leads to a decrease of iron efflux by a direct effect of the hormone on the
amount of ferroportin expressed on cellular membranes of enterocytes and macrophages. Indeed,
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hepcidin binds to ferroportin and, after phosphorylation of a specific Tyr residue, directs the protein
to degradation and thus controls iron efflux from cells [11]. Ferroportin is the only iron efflux pump
in macrophages [8] and, in the enterocytes, mediates iron efflux through the basal membrane, thus
regulating iron intestinal absorption. Owing to its role in iron cellular efflux, ferroportin degradation
has two major consequences: (i) a decrease in iron absorption in the intestine and (ii) a decrease in the
extracellular iron concentration following sequestration within macrophages. This innate immune
response results in the iron starvation of extracellular pathogens and the increased availability of iron
for intracellular pathogens, especially those residing in the macrophages like Salmonella ssp. However,
macrophages also use iron to activate the oxidative burst that follows bacterial infection and the
subtle interplay between iron availability to the pathogen and its effective use as antibacterial needs
further clarification [8]. Also, lactoferrin is induced during infection and it is likely to support the
iron-requiring reactions of the oxidative burst [26]. As mentioned above, also Hp and hemopexin
expression is stimulated during the acute phase of bacterial infection, together with that of lipocalins.
Lipocalins are a large protein family composed of structurally similar but functionally heterogeneous
proteins that fulfil diverse functions [34]. Most of the family members show a distinctive β-barrel
structure that folds in a cup-shaped cavity able to recognize and bind many different molecules
ranging from retinol to dyes and pheromones. Specialized lipocalins, known as siderocalins, are able
to bind bacterial siderophores [35], thus competing with bacterial mechanisms of iron uptake (see
paragraph 2.1). Interestingly, bacteria have evolved the so-called “stealth” siderophores, non-canonical
iron-chelating molecules that are not recognized by lipocalins. To date only Salmonella spp., Klebsiella
spp. and Bacillus anthracis, but not S. aureus, have been reported to produce stealth siderophores [36,37].
Indeed, the number of siderophores produced by S. aureus is comparatively limited, but the bacterium
is able to import exogenous siderophores including the stealth siderophore salmochelin (vide infra).
Taken together, the above-mentioned mechanisms constitute the so-called hypoferremia/anemia of
infection that leads to a decrease in the total iron concentration in body fluids from 10–30 micromolar
to concentrations lower than 10 micromolar following infection by a pathogen [38]. The relevance
of iron-withdrawal strategies in fighting bacterial infections is evinced by the reported increased
susceptibility to bacterial, viral, and protozoan infections of individuals, whose ability to withdraw
iron is compromised or who experience a sudden iron overload [39]. It is also historically supported
by the ancient clinical practice of bloodletting, used for more than 2500 years to treat a variety of
diseases, including bacterial infections [40]. Medical literature reports several examples of a positive
correlation between plasma iron concentration and susceptibility to infections. However, in many cases
the mechanism underlying increased susceptibility to infections is not completely understood. For
these reasons, we report below some representative examples, and the reader is referred to the original
works for a critical evaluation of the single cases. A good starting point is the review by Weinberg [39].
Newborns are especially susceptible to iron overload-related infections due to a less efficient
transferrin production. One striking example is the seven-fold increase in septicemia and other bacterial
infections in newborns treated with iron dextran in comparison with untreated neonates [10,39]. Iron
overload can favor the shift from latent to manifest infections by, e.g., Yersinia enterocolitica and
Salmonella [41,42]. Sickle-cell anemia and conditions displaying an increased rate of hemolysis are
closely associated with an increased susceptibility to bacterial infections. For example, hemodialysis
patients are more susceptible to infections-related morbidity and mortality [39]. The never-ending war
between host and pathogens for iron acquisition is extraordinarily complex and especially fascinating
in the case of commensal pathogens, like S. aureus and Pseudomonas aeruginosa, that can acquire the
capability of infecting the host after a long period of cohabitation. Nutritional immunity can contribute
in keeping the pathogen under control (asymptomatic colonization or localized disease) until some
poorly characterized stimulus causes a shift to the infective phenotype. This review focuses on a
commensal organism, S. aureus, that is listed among the most threatening pathogens in the World
Health Organization priority list (a list of bacteria for which new antibiotics are urgently needed) [43].
S. aureus is also one of the most representative examples of the pathogens’ ability to acquire resistance
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to multiple, if not all, antibacterial drugs developed so far. This review has the intent of showing a
potential way towards the exploitation of iron withdrawing strategies, selected by millions of years of
evolution, in the treatment of staphylococcal infections [44,45].Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 50 
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Figure 1. Schematic illustration of human proteins recruited in iron sequestration within the nutritional
immunity (left), and Staphylococcus aureus effectors in iron retrieval (right). For protein representation,
the following Protein Data Bank entries have been used: transferrin (1d3k), lactoferrin (1b0l), ferritin
(1fha), hemopexin (1qhu), Hp 1-1 (extracted from 4wjg), IsdBN1N2 (extracted from 5vmm), IsdHN2N3
(extracted from 6tb2), FepB (3o72, illustration of the homolog Escherichia coli EfeB), and Hb/heme/iron
(1a3n). Staphyloferrin A and B, and staphylopine have been modelled on the basis of Endicott et al. [46]
and Deane [47] works, respectively. Proteins are divided into three groups based on the source of iron
they exploit.
2. Mechanisms of Iron Acquisition by Staphylococcus aureus
S. aureus acquires iron from several human host sources, depending on the site of infection and
its growth phase [44,48–52]. During colonization and infection stages, S. aureus can settle in different
niches and experiment alternative nutrient availability [53]. It is speculated that at the beginning
of a bloodstream infection the bacterium can rely on the abundance of hemic iron bound to Hb in
erythrocytes, which can be made accessible through the action of toxins such as hemolysins and
leukocidins. In the scarcity of heme, e.g., in abscess environment, iron can be scavenged in inorganic
form from the host storage proteins transferrin and lactoferrin by iron chelators known as siderophores.
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A consistent array of membrane and cell wall-anchored proteins are devoted to the detection of heme
or iron sources [54,55]. It has been shown that S. aureus can extract heme also from Mb [56], but this
process has been only limitedly investigated. This section is devoted to the presentation of the systems
available to S. aureus to acquire iron from the host. The molecules involved in the mechanisms of iron
acquisition are summarized in Figure 1 and the PDB codes to access the structural coordinates of the
proteins involved are listed in Table 1.
Table 1. Protein Data Bank (PDB) accession codes of proteins involved in iron acquisition by
Staphylococcus aureus.
PDB Codes Protein Reference
3lhs, 3li2 HtsA [57]
3eiw, 3eix HtsA [58]
5d84, 5d85 SbnA [59]
4m54, 4mp3, 4mp6, 4mp8, 4mpd SbnB [60]
4tv5 SbnG [61]
5uje SbnI [62]
6knh and 6kni SbnH [63]
3mwf, 3mwg SirA [64]
4fna, 4fil FhuD2 [65]
4b8y FhuD2 [66]
5twb, 5twc IruO [67]
7ahl Hla [68]
3b07 Hlg [69]
4q7g LukD [70]
3roh LukE [70]
3i41 β-toxin [71]
2kam δ-toxin [72]
1t2p, 1t2w SrtA [73]
1ng5 SrtB [74]
4lfd SrtB [75]
4xs0 IsdH-Hb [76]
5vmm IsdB-Hb [77]
6tb2 IsdH-Hb-Hp [78]
2ite, 2itf IsdA [79]
2o6p IsdC [80]
2q8q IsdE [81]
1xbw IsdG [82]
3lgn IsdI [83]
2.1. Siderophores
Siderophores are low-molecular-weight compounds (500–1500 Da), widespread in plants, fungi,
and bacteria, with high affinity for ferric iron and used to supply the cell under iron starvation
conditions. In microorganisms, siderophores can acquire iron from host proteins like transferrin
and lactoferrin, overcoming the nutritional immunity limitations. Their biosynthesis is regulated
by iron levels and they are generally classified according to their iron-binding moiety: carboxylate,
hydroxamate, catecholate, phenolate, and mixed-type. Like other pathogens, such as P. aeruginosa,
Salmonella ssp., and Escherichia coli, S. aureus synthesizes and secretes siderophores in the extracellular
space and, also, internalizes siderophores produced by other microorganisms. Siderophores, once
bound to ferric iron, are imported inside the cell through an ATP-binding cassette (ABC) transporter,
which is formed by an extracellular membrane-anchored soluble lipoprotein able to bind the substrate,
a transmembrane permease, and an ATPase.
2.1.1. Endogenous Siderophores
Carboxylate-Type Siderophores: Staphyloferrin A and Staphyloferrin B
S. aureus produces and secretes two main siderophores, staphyloferrin A and B (SA and SB,
respectively), and expresses specific uptake systems. SA and SB both belong to the carboxylate-type
siderophores (Figure 2). They are synthesized through a non-ribosomal peptide synthetase-independent
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siderophore (NIS) pathway, which is based on the alternation of dicarboxylic acids (such as succinate,
citrate, and α-ketoglutarate) and diamines, amino alcohols and alcohols building blocks [84]. They
are secreted by S. aureus during iron starvation and are primarily devoted to the scavenging of iron
from extracellular precipitated ferric hydroxides and host proteins, like transferrin and lactoferrin,
thanks to their higher affinity for Fe(III). SA and SB are reported to have different effects on infection
outcomes in animal models and were recently shown by multimodal imaging mass spectrometry to
have heterogeneous distribution across infection loci, suggesting specific roles rather than functional
redundancy [50].
Staphyloferrins are transcribed from two different gene clusters, namely sfa and sbn for SA and
SB respectively, both under Fur (ferric uptake regulator) repression. The synthesis of SA is carried
out by two NIS synthetases, SfaD and SfaB, encoded by two genes divergently transcribed and acting
sequentially by reacting two citrate molecules with D-ornithine [85]. SfaC racemizes L-ornithine to
the D-enantiomer, providing the right substrate for the siderophore synthesis [85]. The citrate for SA
biosynthesis is supplied by the citrate synthase CitZ of the tricarboxylic acid (TCA) cycle, hence linking
the cellular energetic state to SA production [86,87].
Once synthesized, SA is exported from the bacterium by SfaA, homologous to transmembrane
efflux pumps belonging to the major facilitator superfamily (MFS). Deletion of sfaA was shown to give
a drastic reduction of staphyloferrin secretion in the medium, with a corresponding increase of its
cytoplasmic levels in vitro [88], and to induce a growth defect in in vivo infection models [89]. When
SA coordinates Fe(III), the uptake is managed by the Hts (heme transport system) ABC transporter [58],
named for the role of heme uptake system originally attributed to this protein [53]. Hts complex
is formed by the substrate-binding protein HtsA [57,58] and the integral permease heterodimer
HtsBC. Since the operon (htsABC) is lacking a gene encoding for the ATP-binding protein, Hts activity
relies on a promiscuous ATPase, FhuC [58]. HtsA binding to SA has a dissociation constant in the
low/subnanomolar range [57].
The biosynthesis of SB is managed by the sbn gene locus (sbnA–I), which encodes all the enzymes
needed for its synthesis (SbnABCEFGHI) [90]. This operon is found only in the most invasive
coagulase-positive S. aureus strains, whereas the gene cluster for SA synthesis is widespread across
both virulent coagulase-positive and commensal coagulase-negative strains [62]. SB is produced
from one molecule of citrate and α-ketoglutarate and two molecules of L-2,3-diaminopropionic acid
(L-DAP) and presents two isoforms, one with a linear and one with a cyclic hemiaminal α-ketoglutarate
moiety. The latter form is likely the one physiologically present in solution [91]. It has been recently
demonstrated that the citric acid stereocenter is important for the iron chelation properties of SB since it
is necessary to create the coordination sphere around Fe(III) ion [91]. Differently from the biosynthesis
of SA, the sbn gene cluster encodes also the enzymes for the synthesis of the three SB precursors (L-DAP),
α-ketoglutarate (produced by SbnA and SbnB [92]), and citrate (SbnG). SbnA, a pyridoxal-5′-dependent
enzyme, synthesizes N-(1-amino-1-carboxy-2-ethyl)-glutamic acid (ACEGA) and inorganic phosphate
from O-phospho-L-serine (OPS) and L-glutamate [59]. SbnB then hydrolyzes oxidatively ACEGA
in the presence of NAD+ to obtain L-DAP, α-ketoglutarate, and NADH [60]. Citrate is produced
from oxaloacetate and acetyl-CoA by a structurally distinct type of citrate synthase, SbnG [61,93].
It has been observed that SbnG is not able to fully integrate the absence of CitZ for the production
of SA in citZ mutant, thus posing the question of how citrate produced by SbnG is directed on SB
biosynthesis [87]. SbnI encodes an L-serine kinase synthetizing OPS and, in addition, has a role in (i) the
regulation of the staphyloferrin biosynthesis and (ii) the precursors biosynthesis [62]. In fact, it controls
the expression of synthetase enzymes SbnC, SbnE, and SbnF and the decarboxylase SbnH [63], so
controlling the siderophore export through the transporter SbnD. In addition, SbnI can bind a promoter
sequence upstream of sbnC, controlling the transcription of part of the operon. Heme is a ligand of
SbnI and inhibits SbnI binding to DNA, hence a mechanism has been proposed in which S. aureus
senses intracellular heme and consequently modulates SB biosynthesis [94,95]. SB is exported outside
S. aureus by SbnD to capture iron ions [94]. The fact that sbnD mutants have an only partial deficiency
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in SB secretion suggests that also other efflux mechanisms are available for this siderophore [88,89].
The following uptake of Fe(III)-SB is operated by the Sir (staphylococcal iron-regulated) system, which
is encoded by the sirABC operon, adjacent to snb operon but transcribed in the opposite direction [96].
The ABC transporter is composed of the SirA lipoprotein (SB binding protein) [57], SirB and SirC
transmembrane permeases and the promiscuous FhuC ATPase [97]. The dissociation constant between
SirA and SB is in the low nanomolar range [57], similarly to the affinity of HstA for SA.
The utilization of Fe(III) bound to SA needs the activity of NtrA, a specific nitroreductase which
releases iron from SA by its reduction of Fe(III) to Fe(II). On the other hand, the mechanism of
dissociation of Fe(III) from SB inside the cytoplasm is still not characterized, but could be similar,
involving a dedicated reductase. Alternatively, or in addition, unidentified iron chaperones could
participate in iron transfer from SB to SA before the final release of the ligand [98]. However, since
it has been observed that SA-deficient mutants are not showing a growth reduction when SB is still
present, SA may not be the primary actor in the extraction of Fe(III) from transferrin, the main iron
source in serum. Recently, it has been postulated that SA could promote colonization and infections of
the skin and soft tissues, where glucose and iron concentrations are lower and higher, respectively,
than in the serum. The comparison among the infection of a murine animal model with the S. aureus
wild type and sfa and sbn deleted strains supports this thesis, demonstrating that an impaired SA
synthesis affects the bacterial ability to form subcutaneous abscesses [99].
Other Endogenous Iron-Chelators
The existence of a third iron-specific siderophore, named aureochelin, was postulated by Courcol
and colleagues [100]. Its structure, however, has never been characterized [101] and its significance in
staphylococcal metabolism is still debated. In fact, the concentrated culture supernatant from a strain
deleted in both staphyloferrins loci cannot support the wild type growth in iron-depleted conditions [58].
These observations suggest a prominent role of staphyloferrins in total siderophores production.
Together with other siderophores, S. aureus synthesizes a broad-spectrum metallophore known
as staphylopine (StP). The machinery aimed at StP expression and trafficking is encoded by the
cntKLMABCDFE operon [102–104] and its structure and function are similar to the phytosiderophores
precursor nicotianamine, widely distributed in higher plants (Figure 2). StP biosynthesis is controlled
by iron and zinc through the presence of fur and zur (zinc uptake regulator) boxes, and its activity is
directed to the supply of copper, nickel, cobalt, zinc, and iron (in decreasing order of affinity) in the +2
oxidation state [102,103]. It has been demonstrated, both in vitro and in vivo, that an impaired efflux
of StP leads to the metallophore accumulation in the cytoplasm, with detrimental effects on S. aureus
growth [105].
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2.1.2. Exogenous Siderophores
When S. aureus is present in a bacterial community, it takes advantage of its ability to import and
extract iron ions from siderophores produced by other bacteria (xenosiderophores). Xenosiderophores
are imported thanks to the expression on S. aureus surface of specific uptake complexes highly
conserved among different staphylococcal strains [54]. This competence permits the exploitation
of molecules as ferrochrome, desferrioxamine B (DFO), aerobactin, coprogen, rhodotorulic acid,
enterobactin, bacillibactin, salmochelin and 2,3-dihydrobenzoic acid [101,107–109]. These molecules
can be grouped into two major categories, namely hydroxamate and catechol-type siderophores, based
on their structures.
Hydroxamate-type siderophores bind Fe(III) and are imported by the Fhu import system,
organized in an ATPase (FhuC), a heterodimeric permease (FhuBG), and two independently transcribed
substrate-binding lipoproteins (FhuD1D2). FhuC acts as a promiscuous ATPase, serving several
iron-uptake systems, as those involved in staphyloferrins import. FhuD1 and FhuD2 are homologous
proteins whose genes reside outside of the fhuCBG cluster, evidence of evolutive genetic rearrangement
of the staphylococcal chromosome [65,110]. Mutagenesis experiments highlighted a broader ligand
binding ability for FhuD2 than FhuD1 [111].
Catechol-type siderophores’ efficacy in iron binding depends on the high affinity for Fe(III) and
pH sensitivity of catechol. Moreover, they possess a very negative redox potential, giving a high
metal selectivity for Fe(III) over Fe(II) [36]. S. aureus exploits bacterial catechol-based siderophores
but also host catecholamine hormones [109,112]. The latter strip iron from transferrin upon reduction
to Fe(II). Catecholamine-iron complex can be then internalized also in case the aerobic environment
promotes iron reoxidation [112]. Both the categories can be internalized through the SstABCD ABC
transporter [109,113]. The inactivation of sst locus impairs S. aureus viability in heart infection, posing
questions about its role in endocarditis development [109].
FhuD1, FhuD2, and SstD, in comparison with other siderophore-binding proteins, have a lower
affinity for their exogenous siderophore ligands (high nanomolar-low micromolar) but gain in broader
binding capacity, a parasitic behavior which gives to S. aureus a growth advantage with respect to other
bacteria [108,109,111].
Once imported inside the bacterial cell, S. aureus exploits the activity of the nicotinamide adenine
dinucleotide phosphate (NADPH)-dependent iron uptake oxidoreductase (IruO) to extract iron as
Fe(II) from hydroxamate siderophore and allows its metabolism [67,98]. NrtA is not required for
extracting the iron bound to Fe(III)-DFO, while a transfer of ligand from DFO to SA is possible through
the action of IruO, which dissociates iron from DFO; iron is then chelated by apoSA and released again
by NrtA [67,98]. This is a unique example of ligand transfer between siderophores, that could involve
intermediate protein carriers not yet discovered. Interestingly, iruO-deleted strain USA300 does not
increase its virulence during DFO treatment, an opposite phenotype than the isogenic wild type strain
that usually threatens patients’ life assuming DFO concomitantly to a staphylococcal infection [98].
The extraction of iron from catechol-type siderophores in bacteria generally involves the
destruction of the carrier through the action of an esterase, with the concomitant release of unreduced
Fe(III) [114–116]. S. aureus could likely use a similar mechanism, but a homologous esterase has not
yet been identified.
2.2. Hemic Iron
2.2.1. Hemolysins and Leukocidins
The primary supply of iron for S. aureus seems to be heme [53], also known to be the most available
and abundant iron source in the mammalian host (see Section 1.2). Heme is bound to globin proteins,
mainly Mb in the muscles and Hb in the blood. Since Hb is strictly compartmentalized, S. aureus
releases an arsenal of toxins able to kill immune system cells, overcome epithelial and endothelial
tissues, and lyse erythrocytes to provide iron for bacterial growth.
Int. J. Mol. Sci. 2020, 21, 2145 10 of 44
The pore-forming cytotoxins can be divided into three main groups, namely Hla, Hlb, and
Hld, based on their structure and mechanism of action. Their production is controlled by the
regulatory proteins Sae (S. aureus exoprotein expression system), Agr (accessory gene regulator) and
Sar (staphylococcal accessory regulator) to respond to changing microenvironments [117–119]. The first
group is represented by α-hemolysin (Hla), the more extensively characterized hemolysin, classified as
a very relevant virulence factor [68]. Hla is a homoheptameric transmembrane β-barrel forming an
aqueous pore that allows the diffusion of low molecular weight molecules (cut-off 1–4 KDa) such as
ions and ATP [120], leading to necrotic death of the target cell. This toxin is important for S. aureus
virulence in pneumonia, sepsis, septic arthritis, brain abscess and corneal infections [121–124]. As is
the case with Hla, γ-hemolysin (Hlg) and LukED leukocidin are also barrel-forming proteins but
assemble as hetero-oligomers and are known as bicomponent toxins. Their action is central in the lysis
of human erythrocytes [125]. Hlg is a potent toxin functional as HlgA/HlgB or HlgC/HlgB pairs [69],
forming hetero-octameric pores on erythrocytes (HlgAB) and neutrophils (HlgCB) membrane and able
to enhance the survival of S. aureus in human blood [126,127]. LukED [70] is one of the most important
S. aureus virulence factors and plays a critical function in pathogenesis. In fact, the deletion of lukED
in a highly virulent strain results in a remarkable attenuation in mouse model [128,129]. Recently,
experimental data demonstrated the lytic capacity of LukED on erythrocytes and the inhibition of this
process by LukSF-PV (Panton–Valentine leukocidin) [125,130].
The second group of pore-forming cytotoxins comprises the enzyme sphingomyelinase C
(β-hemolysin, or Hlb) but, since its gene is frequently interrupted by the insertion of mobile genetic
elements, its role in virulence is considered to be limited [131].
The third group is represented by membrane-damaging peptides as δ-hemolysin (Hld, identified
as one of the phenol-soluble modulins, PSMs [132]), an amphipathic peptide with antimicrobial activity
and involved in the promotion of allergic response by the host during skin colonization [72,133,134].
Besides their lytic activity, these proteins mediate several moonlighting functions as receptors
activation, interference with immune response pathways, adhesion and biofilm regulation, antimicrobial
activity [135]. Very importantly, the secretion of Hla, Hld, and Hlb, in synergy with other factors,
participates in S. aureus internalization, persistence, and escape from the phagosome in non-specialized
phagocytic cells [136–138] endowing the bacterium with an alternative dissemination pathway.
The hlb, hld, and hlg loci coding for these toxins are present in the majority of S. aureus strains,
with hla almost always present, whereas the conservation of luk locus is still debated [135,139].
2.2.2. Isd System
Isd in Heme Uptake
The iron-regulated surface determinant (Isd) system is composed of nine Isd proteins acting
sequentially, from heme uptake from Hb and Hp-Hb complex, to internalization and iron release [55].
The Isd proteins are encoded within five operons (isdA, isdB, isdCDEFsrtBisdG, isdH, and orfXisdI),
all presenting an upstream fur box controlling their transcription. The first steps of heme acquisition
take place in the extracellular environment, requiring the action of several peptidoglycan-anchored
proteins. The exposure of this array of receptors is the charge of two sortase transpeptidases,
SrtA [73] and SrtB [74,75], recognizing different signal patterns on target proteins (LPxTG and NPQTN,
respectively [140–142]. The gene srtB is inside the Isd cluster, while srtA sequence is outside of this
genomic region; the transcription of both proteins is controlled by Fur. Mutants carrying the deletion
of A or B sortases loci are characterized by a reduced virulence and colonization ability (Table 2) [142].
IsdA, IsdB, IsdC, and IsdH (previously called HarA [143]) are bound to the peptidoglycan surface,
with a different degree of penetration [55]. IsdB and IsdH are the more extracellularly exposed, IsdA is
only partially exposed, while IsdC is almost totally inserted in the peptidoglycan layer. These four
proteins have a C-terminal signal for sortases; SrtA anchors IsdA, IsdB, and IsdH [55,143–145], while
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SrtB anchors IsdC [142]. They all share the same modular structure, composed by domains called
NEAT (NEAr Transporter) [146], able to bind heme, Hb or Hp-Hb complexes.
IsdB and IsdH perform the first step in hemic iron acquisition since they are able to bind Hb [76,77]
or the Hp-Hb complex [78] and extract the heme, two steps operated by distinct NEAT domains.
It has been observed that, while the two Hb receptors have the same heme acquisition capability,
only IsdB seems to be the determinant necessary to S. aureus for virulence and proliferation in mouse
model [56,147–151]. Remarkably, Pishchany and coworkers emphasized a preferential IsdB binding
to human Hb (hHb) rather than mouse Hb (mHb), with a difference of an order of magnitude in the
affinity of the complexes in vitro (5.5 × 10−8 M for hHb versus 9.8 × 10−7 M for mHb) [148]. This
characteristic is conserved among the clinically relevant S. aureus strains, warning about possible
misleading results of pathogenesis studies carried out in mouse models. For this reason, the authors
introduced the use of a mouse model carrying hemizygous humanized Hb [147,148].
Once captured by IsdB or IsdH, heme is unidirectionally transferred to IsdA and then to IsdC
through a NEAT-to-NEAT transfer [79,80,152,153]. IsdA and IsdC, besides their hand-pass role with
extracted heme from upstream to downstream Isd proteins, can also perform a self-transfer reaction
based on self-dimerization [154]. The heme bound to IsdC can be translocated across the cell wall and
transferred to IsdE, an ABC transporter-binding lipoprotein [81,154]. The role of IsdC is to facilitate the
transfer of the heme from IsdA to IsdE acting as the “central cogwheel” [155]. Heme is then transported
inside the cytoplasm thanks to the IsdDEF ABC transporter [55]. The heme inside the cytoplasm
can be degraded by IsdG [82] or IsdI [83], both presenting a heme oxygenase activity [156]. These
proteins are able to distort the heme (heme ruffling), facilitating the formation of the oxidation products
5-oxo-δ-bilirubin and 15-oxo-β-bilirubin—also called staphylobilins—and formaldehyde [157,158].
IsdI and IsdG are paralogous enzymes, probably acting selectively in the different microenvironments
encountered by S. aureus. This hypothesis is sustained by in vivo studies, where strains deleted in isdG
or isdI genes show different levels of virulence with respect to wild type in different organs during
infection in mice [159]. Since IsdI is able to transfer heme to SbnI causing its inhibition, it could have
a regulatory function in SB synthesis [160], thus linking heme and inorganic iron acquisition (see
Section 2.1.1).
The activity of IsdI and IsdG is also supported by other two heme degrading proteins, IruO
oxidoreductase and NtrA nitroreductase, active in extracting iron from SA and hydroxamate
siderophores. IruO and NtrA can degrade heme and facilitate iron release from the porphyrinic
ring [98,161].
Isd Moonlighting Activities
Proteins participating in heme acquisition through the Isd system possess other important
moonlighting functions, involved in immune evasion and adhesion [162]. In iron starvation conditions,
for example, IsdA is expressed on S. aureus surface and, through the polar nature of its C-terminal
domain, confers resistance to the antimicrobial action of serum fatty acids present on host skin as
an innate defense. Patients affected by atopic dermatitis, possessing consequently lower levels of
fatty acids, are more susceptible to skin colonization [163]. Moreover, IsdA NEAT domain inhibits
apo-lactoferrin proteolytic activity and binds human transferrin [164]. IsdH has been proposed to
promote immune evasion by interfering with complement proteins and opsonophagocytosis process
during systemic infections [165]. Several Isd proteins, on the other hand, play the additional role of
adhesins, thanks to their modular structure composed of NEAT domains. They mediate the adhesion
to host tissues and synthetic surfaces coated with plasma proteins, such as fibronectin, fibrinogen, and
vitronectin [162,166]. This is the case of IsdC [167], IsdA [145,164], and IsdB [168,169].
2.2.3. Fep System
The Fe-dependent peroxidase (Fep) system has been identified in S. aureus by Biswas and
coworkers in 2009 and its function has been implicated in the extracellular iron extraction from heme
Int. J. Mol. Sci. 2020, 21, 2145 12 of 44
while preserving the tetrapyrrole ring intact [170,171]. The system, whose expression is regulated
by Fur, comprises three proteins: FepA, predicted to be a membrane-anchored lipoprotein; FepB,
an iron-dependent peroxidase with a typical twin-arginine translocation (TAT) signal peptide that
enables its exportation by the TAT translocon; FepC, an integral membrane protein. FepABC system
is homologous to EfeUOB system from E. coli, which has been shown to recognize heme and allow
periplasmic hemic iron extraction through a deferrochelation reaction [172]. It has been proposed
that FepB can bind heme and reduce iron, then the ferrous ion is internalized by the bacterium
through the action of the membrane-associated proteins FepA/FepC, whose specific role is still
unclear [171]. In addition, FepA and FepB are possible interactors, as their respective functions cannot
be complemented by the homologous E. coli partners [171]. The physiological relevance of this process
has not yet been established, although it could be implicated in external iron detoxification during
oxidative bursts [170].
Fep-TAT system is not homogeneously conserved among staphylococcal subspecies but, with
few exceptions, is generally found in the most aggressive human strains as S. aureus, Staphylococcus
haemolyticus, and Staphylococcus lugdunensis. Moreover, in vivo experiments demonstrated that S. aureus
RN1HG ∆tatAC and ∆tat-fep mutants show an average 1-log decreased bacterial load in comparison
with the wild type in a mouse hematogenic kidney abscess model [170].
2.3. Heme and Iron Homeostasis inside S. aureus
Once internalized, iron and heme follow specific fates, balancing the nutritional needs with
storage and preservation of the bacterium from potential toxicity. Hemic iron can be released by
IsdG or IsdI through their oxygenase activity or, based on the “heme hijacking hypothesis”, the heme
acquired from the host can be exploited as a cofactor in the bacterial heme-proteins, for example in
cytochromes [53,173,174]. This process could possibly be energetically favorable to S. aureus, explaining
its preference for heme as an iron source. Heme homeostasis inside the cell is maintained through
the action of the efflux pump HrtAB (heme regulated transporter), which pumps the excess of heme
outside the bacterium. The transcription of hrtAB is activated by the dimeric heme sensory system
HssRS, which is sensitive to the intracellular concentration of heme [175–177].
S. aureus, like other microorganisms (e.g., E. coli, Helicobacter pylori, Porphyromonas gingivalis,
and Campylobacter jejuni), can store the excess of inorganic ferric iron inside the ferritin-like protein
FtnA [178]. The function of bacterial ferritins differs significantly among bacterial species, from iron
source, to sustain maximal growth in iron starvation, to protection against Fenton chemistry during
oxidative bursts. The staphylococcal ferritin gene ftnA encodes for 19.5 kDa subunits that, based on
the high homology with previously identified ferritins, assemble in a 24-mer protein able to oxidize
Fe(II) to Fe(III) [179,180]. FtnA shares an elevated degree of identity also with eukaryotic ferritins,
conserving the residues involved in iron binding and ferroxidase center formation [181]. In S. aureus,
the transcription of ftnA is controlled by PerR (peroxide-responsive repressor), based on nutrient
availability for S. aureus growth [178,181]. PerR is also implicated in the expression of enzymes
responsible for hydroxyperoxides scavenging and this parallel regulation can be attributed to the
necessity to lock reactive iron during oxidative bursts [182]. This hypothesis is further supported by
the PerR-dependent regulation of the Dps homolog MrgA (metallo-regulated gene A), a protein with
iron-chelating function that protects DNA from oxidative stress damage [178].
3. Effects of Iron Restriction and Mutations of Assimilatory Pathways on Fitness and Virulence
In this section, a survey of the major consequences on S. aureus virulence and fitness of limiting
iron acquisition are reported. A more detailed list of deletion mutants and their effect on virulence in
animal models of infection is given in Table 2, together with relevant references.
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Table 2. S. aureus deletion mutants in animal models of infection.
System Gene Cluster Regulation Strain Deletion Gene Contribution toVirulence in Vivo Mouse Model of Infection
Evaluated District of
Infection Reference
Heme acquisition
Sortases srtA Constitutive Newman ∆srtA Yes C57BL/6, Swiss-Webster
(intravenous)
Kidney [183]
isdC-FsrtBisdG Fur Newman ∆srtA Yes NMRI (intra-articular) Joints, kidney, blood [184]
Newman, USA300 ∆srtA Yes BALB/c (intravenous) Kidney [150]
Newman D2C ∆srtA Yes BALB/c (mammary injection) Mammary glands [185]
Newman ∆srtA, ∆srtA-srtB Yes CD-1 (intraperitoneal), Systemic, joints, [186]
NMRI (intravenous), C3H/HeJ
(bladder), Sprague-Dawley rats
(intravenous)
kidney, heart
Newman ∆srtA, ∆srtA-srtB Yes NMRI (intravenous) Joints, kidney [187]
Newman ∆srtB Mild Swiss-Webster (intravenous) Kidney [142]
Newman ∆srtB Mild NMRI (intravenous) Joints, kidney [187]
Newman ∆srtB Mild CD-1 (intraperitoneal), NMRI
(intravenous), C3H/HeJ
(bladder), Sprague-Dawley rats
(intravenous)
Systemic, joints, kidney,
heart
[186]
Isd isdA Fur Newman ∆isdBH, ∆htsA-isdE No BALB/c (intranasal) Lung [188]
isdB Fur Newman ∆htsA-isdE Yes BALB/c (retro-orbital) Lung, heart, kidney [188]
isdC-FsrtBisdG Fur Newman ∆isdB, ∆isdA Yes BALB/c (intravenous) Kidney [150]
orfXisdI Fur Newman ∆isdC Mild BALB/c (intravenous) Kidney [150]
isdH Fur Newman ∆isdH No BALB/c (intravenous) Kidney [150]
Newman ∆isdB Yes C57BL/6J (retro-orbital) Heart [149]
Newman ∆isdB No C57BL/6J (retro-orbital) Liver [149]
Newman ∆isdA, ∆isdB, ∆isdC Yes BALB/c (retro-orbital) Kidney [151]
Newman ∆isdH No BALB/c (retro-orbital) Kidney [151]
Newman ∆isdG, ∆isdI, Yes BALB/c (retro-orbital) Heart [159]
Newman ∆isdG-I No BALB/c (retro-orbital) Kidney [159]
Newman ∆isdI Yes BALB/c (retro-orbital) Kidney [159]
Newman ∆isdG, ∆isdG-I No BALB/c (retro-orbital) Liver [159]
Newman ∆isdG, ∆isdI, Mild BALB/c (retro-orbital) Kidney, spleen [56]
Newman ∆isdG-I Yes BALB/c (retro-orbital) Kidney, spleen [56]
8325-4 ∆isdH Yes NMRI (intravenous) Blood [165]
∆isdB, ∆isdB-isdH
∆isdH
Hss hssRS
Constitutive,
activated by heme
Newman ∆hssR Mutation increase virulence BALB/c (retro-orbital) Liver [175]
Newman ∆hssR No BALB/c (retro-orbital) Spleen, kidney [175]
Hrt hrtAB HssRS
Newman ∆hrtA Mutation increase virulence BALB/c (retro-orbital) Liver [175]
Newman ∆hrtA No BALB/c (retro-orbital) Spleen, kidney [175]
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Table 2. Cont.
System Gene Cluster Regulation Strain Deletion Gene Contribution toVirulence in Vivo Mouse Model of Infection
Evaluated District of
Infection Reference
Endogenous siderophores
Staphyloferrin
A
sfaABC Fur Newman ∆sfa Yes BALB/c (subcutaneous) Skin [88]
sfaD Fur Newman ∆sfa-sbn Yes BALB/c (subcutaneous) Skin [88]
htsABC Fur
MW2 ∆sfaA Yes Swiss-Webster (intravenous) Kidney [89]
Newman ∆htsA-isdE No BALB/c (intranasal) Lung [188]
Newman ∆htsA-isdE Yes BALB/c (retro-orbital) Lung, heart, kidney [188]
Newman ∆htsB, ∆htsC Yes BALB/c (intravenous) Kidney, liver [53]
Staphyloferrin
B
sbnA-I Fur, SbnI Newman ∆sbnE Yes Swiss-Webster (intravenous) Kidney [90]
sirABC Fur Newman ∆sbn No BALB/c (subcutaneous) Skin [99]
MW2 ∆sbnD Yes Swiss-Webster (intravenous) Kidney [89]
Newman ∆sbnG No BALB/c (intravenous) Heart, kidney, liver [87]
Newman ∆sbnG-citZ Yes BALB/c (intravenous) Heart, kidney, liver [87]
Newman ∆sfa-sbn, ∆hts-sir,
∆sfa-sbn-sst,
Yes BALB/c (intravenous) Heart, kidney, liver [109]
∆hts-sir-sst
Xenosiderophores
Hydroxamate fhuBGC Fur Newman ∆fhuD2 Yes CD1 (intravenous) Kidney, blood [110]
fhuD1 Fur Newman ∆fhuBGC Yes Swiss-Webster (intravenous) Kidney [189]
fhuD2 Fur
Catecholate sstABCD Fur Newman ∆sst Yes BALB/c (intravenous) Heart [109]
Inorganic iron acquisition
Fep tatAC Constitutive RN1HG ∆tatAC, ∆tat-fep Yes BALB/c (intravenous) Kidney [170]
fepABC Fur
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Iron availability is central in bacterial persistence and drives, among the others, the genic regulation
of several operons involved in its acquisition, metabolism, and storage. S. aureus mainly controls
iron uptake and oxidative stress response through Fur, a highly conserved transcription modulator
that binds an inverted repeat target sequence (Fur box) and is present in many Gram-negative and
low-GC-content Gram-positive bacteria. In S. aureus, it is estimated that the Fur regulon comprises
nearly 20 transcription units involving around 50 genes, directly or indirectly controlled. The simplest
regulation mechanism proposed for Fur involves the regulator to be bound to DNA as a Fe(II)-Fur dimer
in iron repletion condition, whilst iron depletion promotes the dissociation of monomeric apo-Fur
from the target sequences, allowing DNA transcription. Concomitantly, many studies also reveal the
existence of several genes requiring Fur as expression activator [190–192], highlighting a complex and
multifactorial influence of this protein on bacterial metabolism. Importantly, Fur participates in the
expression regulation of virulence and immunomodulatory factors and genes involved in oxidative
stress defense (in particular the catalase-coding gene katA), a metabolism intimately connected to the
presence of iron inside the bacterial cell. This role is played together with the transcription regulator
PerR, in turn, responsible for the regulation of Fur, alkyl hydroxyperoxide reductase AhpC and bacterial
ferritins FtnA and MrgA expression [178,181,191]. As a consequence, mutant strains lacking fur show
a decreased fitness during infection and are more susceptible to neutrophil-mediated killing [193],
most likely due to an impairment in oxidative stress defense and the expression of virulence factors.
Interestingly, it was demonstrated that the inactivation of Fur in E. coli leads to an increased antibiotic
resistance insurgence, related to iron-overload-dependent mutagenesis [194]. Indeed, fur deletion
mimics an iron-depleted condition inside the cell and, on one hand, promotes the transcription of the
bacterial iron transporters and, on the other, avoids the production of iron-storage proteins, perturbing
iron homeostasis and inducing oxidative stress. Almost all the operons involved in iron uptake rely on
a direct Fur regulation, ruled by the presence of upstream Fur boxes [90,142,170,191,195–197]. However,
as previously described, S. aureus possesses redundant systems for iron supply and it was demonstrated
that the preferential iron source during early infection is the heme from host hemoproteins [53], the
latter being the most abundant source since the inorganic form is strictly sequestered. Heme was
found to be a direct regulator of SB biosynthesis [95] and the activator of HssSR system for heme
detoxification. Interestingly, deletion of hssSR/hrtAB genes confers a more virulent phenotype to
S. aureus in liver infection, with effects beyond the regulation of heme homeostasis [175–177]. The lack
of these genes, in fact, alters the expression and secretion of several immunomodulatory proteins that
impair the recruitment of phagocytes and granulocytes, challenging host survival. These observations
disclose a complex regulation of iron sensing, where the iron uptake activation depends on nutrients
availability in the specific environment encountered in the infection district and Fur plays a prominent
role in virulence establishment [192,193]. In fact, Fur action overlaps with that of other important
regulation factors, such as Agr, Sae, and Rot (repressor of toxins) [192], creating a complex and still
not fully understood signaling network. Together, based on iron availability, these proteins control
bacterial physiology and virulence through the expression of hemolysins, adhesins, leukocidins, and
drive the formation of biofilms. For instance, Hla, HlgC, and LukED were found to be upregulated in
a fur-deleted strain [193]. This complex interplay is mostly indirect and likely mediated also by the
transcription of small RNAs, whose metabolism is a matter of several studies. Recently, the sRNA S596
(homologous to E. coli RyhB and controlled by Fur [198]) was identified and predicted to repress the
expression of iron-related genes and TCA cycle enzymes like the citrate synthase CitZ, controlling SA
production [199,200]. This metabolic rearrangement tuned by Fur is known as “iron-sparing response”
and decreases the iron need of the bacterium through a limitation in non-essential iron-containing
enzymes expression. The TCA cycle, that comprises iron-sulfur clusters-depending enzymes, is one
example of this metabolic switch. In fact, S. aureus can upregulate the glycolytic and fermentative
pathways, compensating its energetic requirements [87]. In this situation, S. aureus multifaceted ability
to acquire iron allows the SB biosynthesis even in the absence of TCA citrate, sustained through SbnG-I
catalytic activities (see Section 2.1.1) [62].
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Staphylococcal fitness in host invasion is partly attributed to the proficiency in iron acquisition
through multiple mechanisms. Each of them relies on protein complexes, employing at least
one ABC-transporter importing iron across the membrane, an ATPase and a membrane-anchored
lipoprotein [54,201]. This last type of proteins belongs to the class known as iron-regulated lipoproteins
(IRLPs) and utilizes the acylated moiety in the recognition and binding of iron, driving its internalization
across the membrane through the cognate transporter. IRLPs are recognized as PAMPs by the Toll-like
receptor 2 (TLR2), influencing the host innate immune response [202–204]. It has been demonstrated
that IRLPs, despite inducing an immune response, enhance bacterial fitness and are fundamental in
persistence of infection [205]. Thus, mutant strains lacking the enzyme lipoprotein diacylglyceryl
transferase (Lgt, responsible for IRLPs acylation) evoke the expression of a different array of cytokines
than wild type S. aureus, weakening the host antimicrobial response, and, more importantly, are unable
to adapt their iron acquisition strategy in response to the inflammation-dependent restriction [205].
In addition, the length of the acyl group influences the recognition ability of the immune system,
balancing the presence of S. aureus as a commensal or a pathogen [204].
4. Antibiotic Strategies Targeting Iron Uptake in S. aureus - Small Molecules
In the present section, we review the iron-related systems that can be targeted, or exploited, for
the development of possible antimicrobials and the strategies investigated up to now. The section has
been divided into paragraphs that report targets belonging to pre-iron-uptake systems (secretion of
hemolysins), iron-uptake systems (siderophores and iron mimetics), and post-iron-uptake systems
(heme degradation).
4.1. Targeting Pre-Iron-Uptake Systems
4.1.1. Quorum Sensing Inhibitors
The production and secretion of hemolysins is part of a more generic mechanism, called
quorum-sensing (QS), by which S. aureus undergoes a transformation from harmless to virulent
for the host organism [118,206]. Hla and Hld are mainly positively regulated by the accessory gene
regulator (agr) locus, part of a QS system [207]. The agr operon consists of four genes (agrBDCA) that
encode for the respective AgrBDCA proteins. For a more detailed description of this QS system please
refer to [208–210].
Administration of quorum-sensing inhibitors (QSI) or quorum-quenching agents (QQA) leads to
inhibition of virulence factors expression, which makes bacteria less aggressive and more susceptible
to natural immunity. Antivirulence agents are neither bactericidal nor bacteriostatic and in principle
should be less susceptible to resistance. Many efforts have been done in that direction and, even though
there is currently no antivirulence agent in clinical use, several studies show the usefulness of these
compounds, alone or as adjuvants in conventional antibiotic therapy for methicillin-resistant S. aureus
(MRSA) infections. Indeed, the combination of an antibiotic with an antivirulence agent constitutes a
potential new mode of treatment that may alleviate the antibiotic resistance crisis.
Ideally, inhibition of the agr operon and the toxin production can be achieved by targeting any
component of the system. The most exploited strategies are reported hereafter.
The interaction between the cytoplasmic protein AgrA, acting as a transcription factor of agr operon,
and the bacterial promoter has been extensively studied. The AgrA C-terminal (AgrAC) DNA-binding
domain LytTR was identified as a druggable site, with the aim to inhibit the engagement with the
bacterial DNA. In the same study, a screening of 500 fragment compounds led to the identification
of three molecules able to inhibit AgrA DNA binding activity in the range of 10−4 and thus can be
considered a good starting point for further drug development [211–213].
A series of biarylhydroxyketones was discovered in 2013 to inhibit in vitro MRSA-triggered
erythrocyte hemolysis by 98% at a concentration of 1 µg/mL [214,215]. The survival benefit of the
treatment with these compounds was also assessed in vitro and in vivo, alone or in combination with
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β-lactam antibiotics to which MRSA is resistant in monotherapy. Notably, even though monotherapy
with QQA did not significantly reduce bacterial load compared to control mice, it did confer 100%
survival and relatively good health status to animals inoculated with a lethal dose of MRSA, thus
potentially representing a novel non-antibiotic therapy [216–218].
In 2014, Sully and colleagues [219] identified savirin (S. aureus virulence inhibitor) as an inhibitor
of the agr-specific transcription regulation of the major virulence factors, such as Hla, with promising
outcomes. Interestingly, the compound was also shown to not be subjected to tolerance or resistance
mechanisms. The same group also investigated a series of nine polyhydroxyantraquinones, produced
by Penicillium restrictum, able to bind the AgrAC DNA binding region, among whichΩ-hydroxyemodin
(OHM) was found to reduce dermonecrosis in mouse model of MRSA skin infection [220,221].
The exploration of other bioactive natural products led to the identification of apicidin, a cyclic
tetrapeptide fungal metabolite which, again, demonstrated suppression of agr activation through AgrA
inhibition [222].
Finally, mimetics of the autoinducing peptides (AIPs), which are fundamental for assessing
bacterial population density and interact with AgrC receptors [223,224], have been proposed as
possible novel antimicrobials with extensive structure–activity analysis [225–229].
One concern in the clinical use of QSI is that their efficacy is related to the immune system integrity
(bacterial clearance is host-mediated), meaning that in immunocompromised patients the only use of
QSI could not be enough to overcome an infection.
4.1.2. Small Molecules as Hemolysin Inhibitors
Few hemolysin inhibitors have been reported till now, with mechanistic details mainly explained
by means of in silico studies. According to their mechanism, hemolysin inhibitors may be divided into
two groups: (i) hemolysin monomer binders, which hinder the oligomerization process, and (ii) direct
blockers of the pore formed by the oligomerized Hla subunits. Natural compounds such as baicalin,
cyrtominetin and oroxylin A [230–233], and peptides [234] are included in the first group, whereas
the second group is mainly represented by beta-cyclodextrin derivatives [235,236] or complexes [237],
heparins [238], and isatin-Schiff base Cu(II) complexes [239]. Overall, hemolysin inhibitors effectively
prevent hemolysis in vitro, but without any anti-staphylococcal activity. To date, no lead compound
among Hla inhibitors has been identified.
4.1.3. Iron Chelators
A number of iron-chelating agents, clinically useful in treating iron-overload conditions, have
been evaluated for their ability to inhibit bacterial growth in multidrug-resistant bacteria, mainly by
competing with bacterial siderophores for available iron.
DFO (Desferal®, Novartis), a hexadentate hydroxamate siderophore derived from Streptomyces
pilosus, was one of the first compounds to be investigated as an inhibitor of the in vitro growth of various
Staphylococci, including S. aureus. However, Staphylococci appeared to give different responses to
DFO treatment, with the growth of many S. aureus strains being actually enhanced [240], due to the
ability of these bacteria to capture the xenosiderophore complexed with iron and eventually use it as
an iron source.
Deferiprone (Ferriprox®), a bidentate 3- hydroxypyridin-4(1H)-one (3,4-HOPO) chelator (Figure 3),
is a more recent synthetic, FDA-approved, oral chelator for iron overload due to blood transfusions
in thalassemia major patients. Even though at high concentration, with MICs typically >68 µg/mL
(>0.5 mM), it was found to inhibit - or at least to not promote - the growth of Staphylococci including
S. aureus [240,241]. Deferiprone showed a synergic effect when tested in combination with the heme
analogue Ga protoporphyrin against S. aureus biofilms in in vitro and in vivo infection models [242,243].
It has been speculated that the low activity of deferiprone is due to the ability of bacteria to passively
internalize it, as a result of its low molecular weight. The strategy followed to improve the antimicrobial
activity of deferiprone was to either chemically link many 3,4-HOPO iron-binding moieties to give
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hexadentate dendritic chelators, or to incorporate them into a sufficiently large linear polymer, in order
to make it unrecognizable and less accessible for bacterial internalization [244–248]. DIBI, a 3,4-HOPO
derivatized water-soluble poly-vinylpyrrolidone co-polymer (Figure 3), displayed more than 70 times
lower MIC values in vitro than the chemically related deferiprone. DIBI was also evaluated in vivo,
where it exhibited a dose-dependent suppression of infection, as well as reduced wound inflammation
and staphylococcal burden. When administered in combination with sub-MIC concentrations of the
antibiotics gentamicin, ciprofloxacin, and vancomycin (conditions generally favorable for microbial
re-growth/infection and positive selection of antibiotic-resistant survivors), the Fe-restricted growth
resulting from the presence of DIBI enhanced the overall activities of the three antibiotics and promoted
additional and prolonged bacterial killing [249].
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The Deferiprone chemically related iron-chelating moiety 1-hydroxy-2(1H)-pyridinone
(1,2-HOPO), linked to a triaza-mac ocyclic backbone scaffold to give a hexadentate chelator, was also
evaluated for its inhib tor activity against Gram-negative and Gram-positive bacteria, among which
S. a reus [250].
Despite their unquestionable ability to chelate and thus eliminate the free iron as a source of
bacterial nutriment, th e compounds exhibit relevant MICs decrease only in combination with
antibiotics. This could be attributed to the many r dundant mechanisms that S. aureus possesses to
supply iron defi iency, including the expression of the Isd syst m proteins.
4.2. Targeting the Iron-Uptake Systems
4.2.1. Exploiting the Iron-Uptake System
Trojan Horses
Siderophores have been envisaged as “Trojan horses”, for their capacity of entering bacteria
and deliver therapeutic agents conjugated to the siderophore molecule (Figure 4). Even if covalently
conjugated with other molecules, for instance, antibiotics, siderophores are often recognized by their
transporters, which pull them inside bacterial cells. Here the conjugated molecule can be released and
exert its action [251–253].
This strategy has been first exploited by the same bacteria for delivering antibiotics in competing
organisms able to internalize xenosiderophores. These conjugated compounds, constituted by a
siderophore and a covalently bound antibiotic, were identified for the first time in 1947 in Streptomyces
strains [254], before the discovery of siderophores. They were found to compete with the siderophore
uptake system and first named sideramines or siderochromes. They were later referred to as
sideromycins, and their structure was properly defined only in 1982 [255].
Int. J. Mol. Sci. 2020, 21, 2145 19 of 44
Albomycins, the first discovered sideromycins, present a ferrichrome-like trihydroxamate
siderophore linked to a seryl-thioribosyl pyrimidine. They inhibit seryl-tRNA synthetase and have a
broad-spectrum activity towards both Gram-positives and Gram-negatives, with MIC in the order
of 5 ng/mL [251,256]. The FhuA and FhuD ferrichrome membrane transporters, capable of actively
transport siderophores and siderophore derivatives through the bacterial cell, are responsible for
this high potency. Once in bacteria, the antibiotic is released by a serine protease, which cleaves the
amide bond linking the two moieties. While the antibiotic remains within the cell, the iron-free carrier
is released.
Salmycins were later isolated from a Streptomyces violaceus strain [257]. They are formed by a linear
trihydroxamate siderophore (danoxamine) belonging to the ferrioxamine family, a succinoyl linker
and an aminoglycoside, which inhibits protein synthesis. Differently from albomycins, salmycins
are selective towards Gram-positives, with MIC values in the order of a few ng/mL [251]. Again, the
extremely high potency can be attributed to the specific transport mechanism that occurs by means
of hydroxamate siderophore membrane transport proteins [258]. Unfortunately, the in vivo activity
towards S. aureus is not so high and the compound has to be administered at shorter intervals with
respect to other antibiotics as vancomycin and rifamycin, possibly because of the instability of the ester
linkage [251]. Salmycins have been, instead, patented for treating iron-overload diseases [259,260]. Their
applicability has been also supported by the incapability of mammalian siderophore-binding proteins,
i.e., siderocalins, to bind ferrioxamine siderophores, and by the consequently high bioavailability.
Ferrimycins, finally, are constituted by a ferrioxamine B moiety, conjugated to an antibiotically
active group, and specifically target Gram-positives [261].
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As mentioned, despite the quite different nature of the antibiotic moiety, both albomycins and
salmycins are transported by the same siderophore transport proteins.
Sideromycins are equally expressed and potent in Gram-negatives, in which the outer membrane
does not represent a permeability barrier, but actively facilitates their transport. For many antibiotics, in
fact, the diffusion through the outer membrane is so poor that the MIC reaches toxic levels. Exploiting
the siderophore transport system often leads to a 100-fold MIC reduction [263]. Indeed, the same
seryl-thioribosyl pyrimidine moiety of albomycin, without a siderophore carrier, is 30,000-fold less
potent against S. aureus and E. coli, because of permeability issues [251]. As well, the semi-synthetic
CGP 4832 rifamycin derivative was found to be 200-fold more active than the original rifamycin in
E. coli and Salmonella strains [264].
As for other antimicrobials, the same bacteria can become resistant to sideromycins, generally
because of mutations at the level of the siderophore receptor or of the TonB transport complex.
The capability of these conjugates to easily cross the bacterial membrane was soon exploited in
antimicrobial research, and synthetic compounds mimicking natural sideromycins were designed
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using a “Trojan horse” strategy. These molecules contain three components, a natural or mimetic
iron-chelating siderophore, a linker, and an antibiotic. With respect to canonical antibiotics, these
siderophore–antibiotic conjugates generally present an improved selectivity, since each bacterium
produces and uses different types of siderophores. A higher specificity goes in the direction of
more responsible use of antibiotics, because of a reduced risk of antibiotic resistance. Other possible
advantages are related to the enhanced antibacterial potency and the selectivity for pathogenic
strains over non-pathogenic ones, accomplished by the transformation of Gram-positive antibiotics in
Gram-negative antibiotics, which might render multiple drug-resistance bacteria more susceptible [265].
Thanks to the structural tolerance displayed by siderophore transporters, artificial siderophores,
and conjugates quite different from the parent structures can be transported as the natural siderophores
in the targeted bacterial cells. However, the best strategy for the development of a successful synthetic
conjugate relies on the replication of natural siderophores [266,267]. Accordingly, catecholates and
hydroxamates constitute the iron-chelating portion of the majority of the known siderophore–antibiotic
conjugates, being recognized as natural or xenosiderophores by both Gram-negative and Gram-positive
bacteria, respectively [99]. Regarding the linker, a fine balance of chemical reactivity is required, since it
has to be sufficiently stable in the extracellular environment, but cleavable once in the cytoplasm [265].
Finally, β-lactam antibiotics have provided, up to now, the most successful conjugates targeting
Gram-negative bacteria. However, conjugates containing fluoroquinolones have been also developed
to cross the inner membrane and reach cytoplasmic targets of Gram-negative and, in particular, of
Gram-positive bacteria [268].
Among the first to design semisynthetic siderophore–antibiotic conjugates, Zahner and coworkers
joined a sulfonamide antibiotic to ferrioxamine B analogs, obtaining compounds with a limited
spectrum of action against S. aureus [269]. Later, Ghosh and Miller combined catechol and
mixed catechol-hydroxamate ligands with the Gram-positive antibiotic vancomycin, to synthesize
conjugates that showed a reduced activity with respect to the antibiotic alone [270]. Differently,
a hydroxamate-5-fluorocytosine conjugate, properly designed to undergo ester-mediated cleavage,
demonstrated enhanced activity towards Staphylococcus and Enterococcus spp., when compared to the
5-fluorocytosine active metabolite alone [271].
Inspired by natural salmycins, Wencwicz and colleagues designed a series of linear hydroxamate
siderophore-fluoroquinolone conjugates to target S. aureus [262]. The authors started from the salmycin
siderophore portion containing a succinoyl linker and synthesized six derivatives with an increasing
number of hydroxamate groups (from one to three), conjugated to the broad-spectrum β-lactam
carbacephalosporin Lorabid, having a periplasmic biological target, and to the broad-spectrum
fluoroquinolone ciprofloxacin, targeting the cytoplasmic DNA gyrase. In general, the β-lactam
derivatives demonstrated a narrower spectrum of action and a reduced potency against the ESKAPE
bacteria group (Enterococcus faecium, S. aureus,Klebsiella pneumoniae,Acinetobacter baumannii, P. aeruginosa,
and Enterobacter species). Moreover, the mono- and bis-hydroxamate fluoroquinolone conjugates
also had a reduced activity spectrum and a reduced potency with respect to ciprofloxacin, while the
trihydroxamate derivative showed selectivity towards Gram-positive S. aureus, maintaining a similar
potency in terms of MIC (1 mM with respect to 0.5 mM). The compound, thus, is one of the very
few synthetic siderophore–antibiotic conjugates capable of maintaining the activity of the original
antibiotic. The narrower spectrum of action must be attributed to the trihydroxamate siderophore, also
known as desferridanoxamine, better recognized, with respect to the mono- and bis derivatives, by
FhuD1 and FhuD2, the promiscuous membrane-anchored hydroxamate siderophore binding proteins
of S. aureus. Gram-negatives have more selective siderophore binding outer-membrane proteins,
possibly unable to recognize these derivatives. The lack of activity of β-lactam conjugates could be
attributed to the location of the biological target. As the compounds are transferred by active transport
into the cytoplasm, a target as PBPs located in the plasma membrane is not the ideal one. Thus,
when targeting Gram-positives with siderophore–antibiotics conjugates, cytoplasmic targets should
be preferred. The capability of the trihydroxamate-ciprofloxacin derivative to reach the target by
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means of active transport was also demonstrated by the dependence of the antibacterial activity on
iron concentration and the presence of siderophores competing for the same transport mechanism.
As stated by the authors, two main advantages can be associated with the development and use of
trihydroxamate-ciprofloxacin derivatives. First, the selectivity of the compounds towards S. aureus
makes them ideal candidates for targeted antimicrobial chemotherapy, which limits the exposure of
other bacteria to ciprofloxacin and, thus, is less prone to generate multidrug resistance. Moreover, the
compound intrinsic toxicity towards mammalian cells is reduced because siderophore transporters are
absent in eukaryotic cells. On the other side, the limits associated with “Trojan horse” compounds
could be represented by a reduced efficacy in treating intracellular infections because of the incapability
of passing eukaryotic cell membrane. Also, the use of a very selective treatment implies an early
detection of the infective agent, with respect to the use of broad-spectrum antibiotics.
In the same period, Milner and coworkers attempted to join the fluoroquinolones ciprofloxacin
and norfloxacin to the same siderophore produced by S. aureus, that is SA [272]. With respect to other
siderophores, staphyloferrin has a higher iron affinity because of its hexadentate nature, is highly
hydrophilic and is an efficient chelator in mildly acidic environments. Unfortunately, when tested on a
panel of 19 reference and clinical isolates, the compounds showed no activity towards ciprofloxacin- and
norfloxacin-resistant strains, and a very reduced potency with respect to the original fluoroquinolones.
When designing a new siderophore-conjugate, Ji and Miller chose DFO as siderophore,
ciprofloxacin as antibiotic and a trimethyl-lock based linker, specifically designed to promote the
antibiotic release by means of esterase or phosphate-mediated hydrolysis [273]. The trimethyl lock
is an o-hydroxycinnamic acid derivative functionalized with three methyl groups, which, by steric
hindrance, induce lactonization and consequent antibiotic release, if triggered by potential esterases
or phosphatases. Ciprofloxacin was chosen again as antibiotic because of the wide spectrum of
action and the intracellular target, while DFO was selected as a well-characterized trihydroxamate
siderophore produced by a number of bacterial species. Two different conjugates were prepared,
plus a control compound having a stable succinyl linker. When tested for their capability to inhibit
bacterial growth in agar well diffusion tests, the two conjugates demonstrated moderate activity against
Gram-negative and Gram-positive strains, including S. aureus. The control compound was, instead, not
active, suggesting it was no more recognized by the membrane siderophore receptors. MIC analyses
confirmed a moderate antibacterial activity against all the strains with the exception of E. faecium.
However, in general, the authors observed a decreased activity with respect to the parent antibiotic
and attributed it to the compounds being poor substrates for esterases. To overcome the risk that the
conjugates could be cleaved by extracellular hydrolases, the same authors proposed similar conjugates
bearing a linker cleavable by ferric reductases, instead of esterases or phosphatases [274]. Upon transfer
of the compound within the bacterial cell, the hydride donors that reduce Fe(III) to Fe(II) should also
reduce the quinone linker, generating a transient hydroquinone, rapidly converted into lactone because
of the “trimethyl lock”. The siderophores were DFO and a mixed biscatecholate-monohydroxamate
ligand designed to exploit multiple siderophore recognition processes. The conjugated quinolone was
ciprofloxacin. The conjugates were found, again, less active with respect to the parent drug in both
Gram-positives and Gram-negatives, possibly because of a more difficult recognition by siderophore
transporters, and a less efficient linker activation within the bacteria. Again, the authors supported the
use of reduction-triggered linkers with respect to more stable ones.
The failure of “Trojan horses” strategies could be attributed to the same specific uptake systems
that make these conjugates particularly active. Indeed, highly modified conjugates could result more
difficult to be transported than native compounds. The presence in bacterial cells of several redundant
iron-uptake systems, able to switch off when needed without affecting the cell survival, represents an
additional failure reason, as well as the necessity to further release from the conjugate the antibiotic, by
means of peptidase- or esterase-mediated cleavage [261]. Fortunately, the chemical space available for
the design of new and more potent conjugates is still very wide. More than 500 different siderophores
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have been reported in the literature, and antibiotics other than β-lactams or DNA-gyrase inhibitors
could be attached to them.
Gallium-Derivatives
Gallium-based molecules have been also classified as “Trojan Horses” for their capacity of being
recognized by the iron transport system. Good antibacterial activities have been shown by simple
gallium salts as nitrate (GaN) or maltolate (GaM) [275–279], and by more complex gallium siderophores
as gallium citrate or by gallium-containing porphyrins [280].
Fe(III) and Ga(III) have a significant chemical similarity, concerning ionic radius, electronegativity,
ligand affinities, and coordination geometry [281]. Accordingly, Ga(III) can be exchanged for Fe(III) in
siderophores, blocking bacterial iron acquisition [282]; it can be taken up as a gallium siderophore
exploiting the iron transport system, perturb the iron acquisition system acting on siderophore
transcriptional regulator, or interfere with the biofilm formation [283,284].
Despite the high similarity, however, Ga(III) cannot be reduced in physiological conditions; thus,
any biological process involving an iron redox reaction, as electron transport or oxidative stress defense,
can be disrupted by the iron-gallium substitution [281,285]. Also, gallium-derived compounds display
quite different pharmacokinetics. For instance, the elimination of Ga-citrate is slower than that of
Fe-citrate and the volume of distribution is six times higher. Interestingly, these compounds are not
expected to be affected by the standard drug resistance mechanisms, as decreased uptake, restricted
bacteria permeability or efflux pumps expression, thus representing interesting strategies to fight
antimicrobial resistance.
Gallium nitrate has been extensively tested towards both Gram-negatives as P. aeruginosa and
Gram-positives as S. aureus. It is well distributed in the body thanks to its binding and transport
by transferrin, and easily taken up by bacteria through the iron transport system. Moreover, it has
been proved capable of disrupting and preventing the formation of biofilms [283]. More complex
systems include gallium citrate, tartrate [281], pyridones [286], acinetoferrin analogs [287], and non-iron
metalloporphyrins (MPs) [288]. The complex formed by gallium and SA, unfortunately, resulted
inactive because internalized with difficulty by S. aureus.
The most promising MPs were first described by Stojiljkovic and colleagues in 1999 [288]. Once
taken up by bacteria heme uptake systems, MPs target the enzymes of metabolic pathways, which
become unable to properly reduce oxygen and induce the production of reactive oxygen species (ROS).
MPs demonstrated to reduce MICs towards different bacteria, including multidrug-resistant ones.
In particular, non-iron protoporphyrin IX including gallium, indium, and manganese was more active
towards Yersinia enterocolitica and Mycobacterium smegmatis, while that including zinc and ruthenium
demonstrated prominent activity against S. aureus [289]. The most promising activity was shown
by Ga-PPIX (Figure 5), probably because of its high structural homology with the iron ion and its
poor toxicity.
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Richter and coworkers recently demonstrated that the combined treatment with Ga-PPIX and
the iron chelator deferiprone significantly reduces the growth of methicillin-susceptible S. aureus
(MSSA) and MRSA [290], and small S. aureus colony variants [243]. Apart from the positive observed
results, it should be reminded that Ga-PPIX-mediated treatments could be cytotoxic because of
the possible interference with host iron metabolism. Researchers observed a loss of cell viability
and an increase in the production of lactate dehydrogenase in cell lines exposed to high Ga-PPIX
concentrations [288,290,291]. It is likely that the Ga-PPIX concentration required to inhibit biofilm
formation is lower than that responsible for cytotoxicity [243], which suggests that a proper balance
between antimicrobial activity and cytotoxicity could be found [292].
Along with Ga-PPIX, also Ga-deuteroporphyrins, Ga-mesoporphyrins, Ga-hematoporphyrins,
Ga-octaethylporphyrins, and Ga-porphyrins have provided interesting activity towards MRSA [289].
Bacteria not targeted by MPs include strict fermenting anaerobes, which do not use heme uptake
systems or cytochromes.
More recently, the antimicrobial activity of Ga-containing compounds was confirmed by Hijazi and
coworkers towards the ESKAPE pathogens, including reference strains and clinical multidrug-resistant
(MDR) ones [293]. The authors compared the activity of three generations of Ga(III) formulations, i.e.,
GaN, GaM, and Ga-PPIX, in culture media having different iron content. The compounds were active
against S. aureus and A. baumannii strains. In particular, GaN and GaM showed a bacteriostatic effect,
while Ga-PPIX had a bactericidal activity on some strains. Interestingly, the latter demonstrated to
be susceptible to the number of bacterial heme uptake systems and the presence of serum albumin,
able to bind a variety of ligands, including heme, and to inhibit their activity. They also confirmed the
susceptibility of all derivatives to the iron concentration (enhanced by iron deprivation) [285], and
of Ga-PPIX to the heme concentration. Indeed, the addition of a 5 mM concentration of heme was
enough to completely abrogate Ga-PPIX activity in S. aureus strains. Overall, being active even in the
presence of serum albumin, GaN and GaM derivatives were the most effective in in vivo mimicking
conditions. It is interesting to note that Ga(III) derivatives already proved to be effective in infections
caused by Gram-negatives [276,294,295].
Apart from Ga-PPIX, Mn-PPIX and Zn-PPIX also exhibit antimicrobial activity against
S. aureus [296]. As already mentioned, Ga-PPIX - but also Zn-PPIX - exert their antimicrobial
activity by inhibiting aerobic respiration through the substitution of heme in cytochromes (a property
also shared by non-toxic non-iron MPs), but also by causing oxidative stress. Interestingly, toxic
non-iron MPs induce the expression of S. aureus heme detoxification system. Upon exposure to heme
toxic levels, in fact, the heme sensor system HssRS is activated and the heme-regulated transporter
HrtAB is expressed [176]. However, HrtAB is unable to detoxify many toxic non-iron MPs. Because of
the massive upregulation, its expression becomes detrimental and increases the bactericidal activity of
these compounds [296].
Photoactive porphyrins have been also used as photosensitizers for the photodynamic inactivation
of microorganisms, based on the generation of singlet oxygen species and free radicals, upon the
activation of the porphyrins by visible light [297]. A cationic tetra-N-pyridyl and a peripheral
[Pt(bpy)Cl]+ substituted porphyrin were evaluated against S. aureus and E. coli strains in dark and
light conditions, showing a lower activity in dark conditions. This supported the photodynamic mode
of action of the compounds [298]. Their efficacy is associated with the interaction they can form with
membrane negative charges that promote porphyrin permeation and accumulation in membranes,
where reactive oxygen species can be generated upon light irradiation.
Overall, Ga-derivatives might represent a powerful resource for the development of new
antimicrobials, to be administered alone or in combination with conventional antibiotics, as recently
demonstrated by Richter and coworkers [242].
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4.2.2. Inhibiting the Iron-Uptake System
In principle, small molecules inhibiting the iron-uptake system may target either siderophore
receptors or hemophores. SA and SB receptors (lipoproteins HtsA and SirA, respectively) bind their
ligands with nanomolar affinity, so that competitive inhibition is precluded. As for xenosiderophores
receptors, up to now, no work has been carried out for investigating whether SstD, or FhuD1 and
FhuD2, are druggable with small molecules. Nonetheless, staphyloferrins and xenosiderophores
receptors have been addressed as promising antigens for staphylococcal vaccines [109] (see Section 5).
The novelty and potential of the recently characterized IsdA-I hemophores have been arousing
interest lately: at the time of writing, hemophores have not been addressed yet as biological targets for
small molecules, although the literature extensively reports their role as antigens in vaccine formulations
(see Section 5) and many authors have suggested their potential exploitation [147,299–301]. Finally,
sortases represent another potential target for therapeutic intervention since their inhibition is expected
to lead to the mistargeting of cell wall-associated proteins. While inhibitors of SrtA should inhibit the
correct localization of many virulence factors in the cell wall (see [302] for a perspective on this topic),
inhibitors of SrtB are expected to more specifically affect iron acquisition through IsdC. Furthermore,
while SrtA is expressed by all Gram-positive bacteria, SrtB is more specific to S. aureus, Bacilli, and
Listeria. However, deletion of SrtB has only mild effects on S. aureus virulence (see Table 2) and a
limited number of works have been reporting positive results on inhibitors development [303,304].
Inhibitors of Siderophore Biosynthesis
The siderophore machinery, being one of the main and most effective systems for iron acquisition,
has been attacked from several fronts with the aim of developing new antimicrobials.
The biosynthesis of staphyloferrin B has been targeted by Tripathi and co-workers [305].
In particular, the authors targeted the type A NIS synthetase SbnE, which catalyzes the condensation of
citric acid with L-2,3-diamino propionic acid [84]. By screening a library of marine microbial-derived
natural product extracts, they identified two new antibiotics named baulamycins A and B (BmcA
and BmcB, respectively). The two molecules demonstrated to act as reversible competitive inhibitors
towards SbnE of S. aureus but also towards AsbA of B. anthracis with IC50 in the micromolar range.
When tested in liquid bacterial cultures they were able to inhibit the growth of both Gram-positive
and Gram-negative bacteria, thus proving the potential of siderophore virulence factor inhibitors as
antibiotics. Being type A NIS synthetases a class of enzymes common to many pathogenic bacteria, they
represent suitable targets for the development of broad-spectrum agents. The strategy of inhibiting
siderophore biosynthesis has been also proven successful in previous studies targeting Mycobacterium
tuberculosis [306–308].
4.3. Targeting the Post-Iron-Uptake Metabolism
Heme Oxygenase Inhibitors
In a recent article, Conger et al. [301] reported the differences between IsdG and IsdI biological roles,
with the former being overexpressed in iron-restricted environment, the latter being constitutive and
limiting iron toxicity, and consequently addressing IsdG as the preferred antibiotic target. Furthermore,
the authors reported low nanomolar dissociation constants for heme-IsdG complexes, hence excluding
the design of competitive inhibitors. Research tracks for IsdG uncompetitive or allosteric inhibitors,
however, remain open. In particular, even if lacking drug-likeness and suffering from consistent
off-target effects, uncompetitive inhibitors such as cyanides and azides have been investigated [309],
while no allosteric inhibitor has been reported yet. Lastly, Conger and colleagues suggested continuing
the exploration of IsdG and IsdI mechanism of action to better design specific inhibitors [301].
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5. Biopharmaceutical Approaches Targeting the Iron System in S. aureus
Biopharmaceuticals are defined as pharmaceuticals obtained by biotechnological processes and
include, inter alia, recombinant proteins, gene therapy, allergenics, living cells, blood components,
antibodies, and vaccines. Among other benefits with respect to small molecules, biopharmaceuticals are
highly specific and could not only treat but also prevent infectious diseases. Hence, as antibiotic-resistant
strains are emerging at an alarming rate, S. aureus has become an enticing target for biopharmaceuticals.
Among these, vaccines may lower the morbidity and mortality rate of staphylococcal infections,
protecting high-risk patients undergoing periodic procedures such as hemodialysis or invasive
surgeries and, ultimately, alleviating the clinical burden. There have been multiple attempts to create a
vaccine against antigens belonging to the staphylococcal iron metabolism but, up to now, all of them
failed to reach the market [310]. Anti-toxin antibodies are another beaten research track for reducing or
treating staphylococcal infections, neutralizing widespread antigens in clinically relevant S. aureus
strains. Furthermore, in this case, to date, no approved therapy is still available. In this paragraph, the
two most relevant macro areas of biopharmaceutical research against S. aureus are addressed, i.e., the
iron/heme uptake system and hemolysins.
5.1. Biologics Targeting the Staphylococcal Iron/Heme Uptake Systems
An early attempt of a vaccine against components of the iron metabolism was reported in 2006 [311]
and was directed towards the cell-wall anchored hemophore IsdB, whose antigenic potential was
discovered in a large in vitro screening of human sera against a library of S. aureus epitopes [312].
Furthermore, IsdB is an extremely appealing target as it is conserved among different clinically relevant
strains and highly expressed in vivo, both in sensitive and resistant bacteria [311]. Hence, remarkable
efforts were made for developing a prophylactic monovalent vaccine against IsdB (V710, by Merck
Sharp & Dohme Corp) between 2006 and 2011, to prevent S. aureus infections. In the preclinical phase,
inoculation of purified IsdB had a protective effect on murine models challenged with several lethal
and sub-lethal doses of S. aureus, while rhesus macaque species responded to immunogenic assays
with long-lasting anti-IsdB titers [311]. Unfortunately, even if phase I (NCT00303069, NCT01324440,
NCT00822757, NCT00735839) and phase II (NCT00572910) clinical trials successfully proved the safety,
immunogenicity, and non-toxicity of V710 [313–315], the anti-IsdB vaccine pipeline was discontinued
in phase II/III. In fact, a double-blind placebo-controlled worldwide trial (NCT00518687) highlighted
not only that administration of V710 did not exert a protective effect against S. aureus, but also that
V710-induced antibody response could be linked to a five-fold higher mortality by post-surgery
staphylococcal infections, compared to the placebo group [316].
The paradoxical results of V710 phase III trial were a matter of speculation in articles and
retrospective studies [317–319]. McNeely et al. [318] pointed out the positive correlation between low
serum levels of interleukins IL2/IL17a before and after vaccination and increased mortality rates by
post-operatory S. aureus infections. In the same work, the authors hypothesized that V710 may trigger
an original antigenic sin mechanism, hence causing a suboptimal or even ineffective response when
the organisms are challenged with S. aureus natural infections. Other remarkable limitations possibly
explaining the detrimental outcome of V710 vaccine include overrating the humoral immunity for
preventing S. aureus infections while neglecting the importance of cellular-mediated immunity [316,320],
and discoverable immune idiosyncrasies, which may heavily impact the efficacy of staphylococcal
vaccines [318]. At the time of writing, the exact physio-pathological mechanism underlying the
increased mortality caused by V710 in S. aureus infected patients is still missing, and this lack of
knowledge has been linked to lurking variables not documented in the original study, such as the site
and the severity of the post-operatory infections [318]. Importantly, for overcoming the limitations
encountered by V710 and for designing more effective next-generation vaccines against S. aureus,
recent literature [320] suggested refinements to be adopted for future research, such as a multi-antigen
approach, preclinical studies involving infections models other than murine, or adopting different
strategies depending on the site of infection. Parallel to the development of V710, research evaluating
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the addition of IsdA in multi-antigen vaccines has been carried out in rodent models, but without any
further follow-up in clinical trials to date [151,321,322].
Extra work has been carried out to characterize the human humoral response to S. aureus and
IsdB in particular [323,324]. In 2016, Yeung et al. [323] detailed that the adaptive immune response
can encode antibodies with motives inherently able to recognize NEAT1 and NEAT2 domains in IsdB.
Antibodies encoded by germline genes IGHV4-39 and IGHV1-69 have been reported to have an almost
identical binding mode on IsdB NEAT1 and NEAT2 domains in X-ray crystal structures deposited in
Protein Data Bank (PDB codes 5d1q, 5d1x, 5d1z [323]). Similarly, in a more recent work, Bennet and
coworkers [324] described at least three binding sites for IGHV1-69-encoded monoclonal antibodies
(mAb) on IsdB NEAT2. In particular, mAb STAU-281 demonstrated a promising protective effect on
liver, heart, and kidneys when tested on mice. The authors further reported the binding mode of three
mAbs on NEAT2 domain, where loops CDR-H2 and CDR-H3 are mainly involved in the interaction
with the heme pocket.
Recent studies [66,110,325] identified the widespread and conserved staphylococcal
iron-hydroxamate-binding lipoprotein FhuD2 as another promising vaccine-target candidate, inducing
a protective immune response in murine abscess and sepsis models. Learning the lesson from
the outcomes of the monovalent V710, the authors suggested using FhuD2 antigen as a part of
multicomponent vaccines and, accordingly, in late works FhuD2 has been included in multi-antigen
formulations [326,327].
5.2. Biologics Targeting Staphylococcal Hemolysins
Biologic products against hemolysins make up the second substantial part of biopharmaceuticals
against the staphylococcal iron system and consist of either immunotherapeutics or vaccine candidates.
Significantly, in vivo tests demonstrated avirulence of staphylococcal strains deficient in hemolysin
production [123].
The literature focuses on neutralizing antibodies against hemolysins (Hla in particular) as a
possible platform for the development of active or passive immunization therapies against S. aureus
infections [328–331]. Hua et al. [329] demonstrated that the administration of anti-Hla antibodies not
only reduces murine abscess models, but also prevents and treats lethal S. aureus-induced pneumonia
in mice. Furthermore, anti-Hla mAbs have been successfully combined with last-generation antibiotics,
such as vancomycin and linezolid, enhancing or synergizing their activity [329,331]. Experimentation
on ASN100, a monoclonal antibody targeting alpha-hemolysin and other cytokines, was terminated
after a phase II trial (NCT02940626), due to its ineffectiveness in preventing pneumonia [332]. IBT-V02
is a preclinical heptavalent vaccine candidate in the Carb-X pipeline [333].
Currently, there are two vaccine candidates against Hla as promising adjunct treatments for
S. aureus-induced nosocomial pneumonia, namely suvratoxumab (MEDI4893, an mAb sponsored
by MedImmune LLC - now AstraZeneca), that proved to be safe and effective in a phase II study
(NCT02296320) [334], and tosatoxumab (commercial name Salvecin™, previously AR-301 or KBSA301,
by Aridis Pharmaceuticals), a human mAb that successfully completed phase I/II clinical trials
(NCT01589185), currently under phase III evaluation (NCT03816956) [335].
The interaction between Hla and a human-derived antigen-binding fragment (Fab) has been
characterized by Foletti et al. [331], who reported the crystal structure of Hla bound to a hinge lined
by CDR-H1, CDR-H2 and CDR-H3 loops of the antibody heavy chain (PDB code 4idj). Rouha et al.
described a multi-specific human mAb able to bind Hla and other four cytolysins [336].
Overall, other hemolysins aroused far less interest. These include a neutralizing antibody
targeting Hlb reported by Pooja and coworkers [337] and a bivalent antibody binding HlgC described
by Laventie et al. [338].
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6. Conclusions
Targeting the iron-acquisition systems shows promise in the discovery of new anti-staphylococcal
agents since the approach should in principle allow to decrease the chance for resistance development
and selectively hit pathogenic bacteria without disturbing host microbiota or promoting the insurgence
of opportunistic infections by Clostridium difficile. The main issue affecting the development of effective
new antimicrobials is related to the presence of several redundant iron-uptake systems that can
switch on and off according to external stimuli, without affecting bacteria survival. Targeting the
pre-iron-uptake system through QS inhibitors could represent a valuable strategy, in particular, if
antivirulence agents are administered in combination with antibiotics. Still, QS inhibitor activity is
strictly related to the human immune system integrity. Hemolysin inhibitors, even if preventing
hemolysis, do not have anti-staphylococcal activity and iron chelators are, again, effective only in
combination with antibiotics, since S. aureus can acquire iron in different ways. The iron uptake system
has been widely investigated as a possible target, mainly through the design of Trojan horses, originally
developed by bacteria to counteract competing organisms. These molecules could be ideal candidates
for their high selectivity and reduced toxicity. Even if highly modified conjugates have resulted difficult
to be transported, the available chemical space is large and more effective combinations can be evaluated
in the future. Similarly, also Gallium derivatives can be recognized by the iron transport system and
have proved their antimicrobial activity when administered alone or in combination with conventional
antibiotics. Siderophores and free iron uptake are not the only targetable systems. Indeed, IsdB and
IsdH hemophores represent another essential way of iron acquisition and, accordingly, a promising
and yet unexplored resource for the design of new antimicrobials affecting heme scavenging. In the
post-iron-uptake metabolism, heme oxygenases, in particular IsdG, offer interesting perspectives too.
Above all, biopharmaceuticals represent, today, the most advanced and concrete possibility. Apart
from the yet unexplained failure of V710, the monovalent vaccine against IsdB, two vaccine candidates,
suvratoxumab and tosatoxumab, targeting hemolysin H1a, have proved their efficacy and safety in
phase II clinical trials, and represent the most promising perspective in the fight against S. aureus.
Finally, the development of new in vitro/in vivo models to test the efficacy of molecules in the early
stages of development will be of great value to allow the identification and the fast progression in the
discovery pipeline of the more promising candidates.
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